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broad series of topics ranging from com-
munication issues with patients to helping
physicians deal with psychological and eth-
ical issues. Although it is aimed at health
care providers who care for patients facing
serious illnesses, it is a relevant resource for
anyone who wants to learn more about pal-
liative care. Overall, Care at the Close of
Life is a very informative and a must-read
for those who are caring for patients with
life-limiting illnesses. Not only does it give
health care providers an understanding of
what needs to be addressed clinically, but
perhaps  more  importantly,  it  allows  for
providers to give insight into the experi-
ence, intuition, and compassion necessary
to care for patients — qualities that often
take years to develop. 
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Both biotechnology and pharmaceuti-
cal companies work to generate products
that will improve the quality of human life.
In recent years, the development of thera-
peutics has evolved considerably. Transla-
tional  Medicine  and  Drug  Discovery
explains the advances in drug development
and  discusses  the  flaws  in  the  current
methodology as well as how those flaws
might be addressed.
The book begins with a brief discus-
sion of the history of translational medi-
cine  and  notes  that  the  concept  has
prompted the formation of teams within
pharmaceutical  companies  that  follow
drugs  from  early  development  through
human trials. Subsequent chapters describe
pharmaceutical advances in diabetes, ath-
erosclerosis, obesity, bone disorders, neu-
roscience,  and  cancer.  Although  topics
such as drug targets, modeling systems,
and imaging techniques are discussed, the
primary focus of the book is the develop-
ment  and  use  of  biomarkers. The  work
concludes with an overview of coalitions
recently  formed  to  improve  health  care
such as the Innovative Medicines Initia-
tive, the Critical Path Institute, and the
Biomarkers Consortium.  
Many of the authors and the editors of
Translational Medicine and Drug Discov-
ery come from a pharmaceutical or biotech-
nological  background,  which  somewhat
narrows the scope of the book; very little
of the material is derived from academic or
government  institutions.  These  authors
offer valuable insight into industry, yet they
also repeatedly touch on an interesting con-
cept: the need to generate profits. Thera-
peutics and biomarkers are discussed in
terms of risks and profits, and special at-
tention is paid to minimizing failed invest-
ments. Interestingly, the book also offers
several examples of how economic con-
cerns  have  led  to  suboptimal  research,
which has in turn impaired the evaluation
of novel therapeutics. Such examples un-
derline the difficulty of improving patient
care while addressing necessary monetary
concerns. Although there are no obvious
solutions, the final chapter of the book dis-
cusses several possible ways of balancing
economics and therapeutics, such as facili-
tating company collaborations and gener-
ating new testing paradigms that will weed
out false leads at an early stage of develop-
ment.  
While it is not an overly technical or
exhaustive work, Translational Medicine
and Drug Discovery is certainly not for the
casual reader. It does, however, act as a
useful overview of the principles behind
industrial  therapeutic  development  and
will be of use to those with a scientific or
medical background. Further, those who
are interested in learning about the histor-
ical and ongoing development of biomark-
ers will certainly benefit from reading this
book.  
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